Research & Development
-
Courtesy of Madrigal
As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones
Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a highly targeted patient approach.
By Kelly Bilodeau • Nov. 19, 2025 -
Getty Images
Amylin could reign supreme in the next wave of obesity drugs
With investment in amylin analogs on the rise for weight management, three key candidates are inching closer to critical readouts.
By Alivia Kaylor • Nov. 18, 2025 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
Permission granted by Pfizer
Sponsored by PfizerDeveloping a path forward in cancer cachexia
Pfizer scientists have been working to advance understanding of – and potential treatments for – cachexia.
Nov. 17, 2025 -
Getty Images
The next leap in Alzheimer’s R&D is coming, but not around the corner
While a couple drugs have reached the market, their effects are still modest, and experts say a true paradigm shift is still a ways off.
By Alexandra Pecci • Nov. 17, 2025 -
Permission granted by Alnylam
ProfileRNAi looked doomed to fail — until Alnylam’s science chief found a way
Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.
By Michael Gibney • Nov. 13, 2025 -
Permission granted by Sarepta Therapeutics
Drugs are winning approval even when trials fail — but should they?
About 10% of FDA-approved drugs in recent years have won clearance despite a trial failure, raising safety and ethical concerns.
By Kelly Bilodeau • Nov. 12, 2025 -
Permission granted by eClinical Solutions
Pharma’s clinical trial diversity push faces a new threat
Skyrocketing healthcare costs could deliver another blow to the industry’s ongoing quest to boost representation in R&D.
By Meagan Parrish • Nov. 7, 2025 -
Getty Images
Why Pfizer and Novo are duking it out over weight loss startup Metsera
A brutal bidding war between two industry giants over a clinical-stage drugmaker is a sign of the weight loss arena’s high stakes.
By Michael Gibney • Nov. 6, 2025 -
Getty Images
Chinese drugmaker becomes top trial sponsor — and other clinical trends
The industry’s top indication areas for R&D and other shifts in the clinical trial landscape last year.
By Kelly Bilodeau • Nov. 5, 2025 -
Getty Images
Biotech SpotlightImunon’s non-viral DNA candidate may have cracked the code in frontline ovarian cancer
Imunon is showing off promising phase 3 data at a gynecologic cancer conference this week.
By Alexandra Pecci • Nov. 5, 2025 -
Permission granted by Biogen
Biogen’s yearslong lupus R&D journey could soon pay off
Following a lengthy R&D process, two new molecules from Biogen could add much-needed treatments for a disease that’s been difficult to pin down.
By Michael Gibney • Nov. 4, 2025 -
Permission granted by Manifold Bio
Roche taps an AI specialist to craft new brain drugs
For $55 million, Roche gains access to Manifold Bio’s drug discovery technology, which will be used to develop new “shuttles” that can get medicines across the blood-brain barrier.
By Jacob Bell • Nov. 4, 2025 -
Getty Images
One of the few late-stage ALS contenders hits a critical juncture
MediciNova has launched a potentially pivotal trial for what it hopes is a disease-modifying ALS drug.
By Meagan Parrish • Oct. 31, 2025 -
deliormanli via Getty Images
Corporate venture firms stepped in for drug startups during biotech funding pullback
According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.
By Gwendolyn Wu • Oct. 31, 2025 -
Courtesy of Novo Nordisk
What comes next for Novo Nordisk?
After losing its leading position in obesity, changing its CEO and triggering a major company reorganization, the pressure is on Novo to pull off a major about-face.
By Kelly Bilodeau • Oct. 29, 2025 -
Getty Images
Novartis’ $12B Avidity deal shows a willingness to take big swings in neuroscience
A premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at revolutionary technology that fits into their own expertise.
By Michael Gibney • Oct. 28, 2025 -
Alamy
Merck’s oncology prospects could portend a post-Keytruda future
Can the pharma giant offset potential losses from its megablockbuster with a strong suite of contenders?
By Kelly Bilodeau • Oct. 27, 2025 -
Permission granted by Biogen
Sponsored by BiogenHow limited options for lupus patients and the challenge of a complex disease drove my mission for change
Lupus is a complex disease – Biogen is seeking to develop potential new treatment options and new hope for patients.
By Youmna Lahoud, MD, FACR, Medical Director, Clinical Development Immunology at Biogen • Oct. 27, 2025 -
Getty Images
Takeda stakes more than $11B on cancer drugs from China
The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be “transformative” for its oncology portfolio.
By Ben Fidler • Oct. 24, 2025 -
Alamy
AI giants Nvidia, Microsoft and Google are making critical moves in pharma R&D
With market caps in the trillions, these tech behemoths are establishing a growing presence in drug development. Here’s what they’re up to.
By Alexandra Pecci • Oct. 22, 2025 -
Alamy
AstraZeneca, Daiichi’s Datroway excels in hard-to-treat breast cancer
Presented at the European Society for Medical Oncology, study results showed Datroway extended survival in breast cancer patients for whom immunotherapy is not an option.
By Delilah Alvarado • Oct. 21, 2025 -
Getty Images
Too much of a good thing? A flood of data is slowing clinical trials.
Pharma companies want to know it all — but cutting out unnecessary data collection could speed drug R&D.
By Kelly Bilodeau • Oct. 15, 2025 -
Getty Images
What a gene therapy win means for the Huntington’s disease pipeline
Recent results for a Huntington’s gene therapy confer a hopeful sign for R&D in the space.
By Kelly Bilodeau • Oct. 14, 2025 -
Permission granted by Colossal Biosciences
Beyond dire wolves: Could Colossal’s de-extinction work transform human health?
While resurrected animal species grab headlines, Colossal’s behind-the-scenes R&D may be poised to make an impact for humans as well.
By Meagan Parrish • Oct. 10, 2025 -
Chris Jackson/Getty Images via Getty Images
Nobel Prize victory spotlights immunology’s value in pharma
While saturated with mature blockbusters, the immunology space is vibrating with new potential breadwinners from the top companies.
By Michael Gibney • Oct. 9, 2025
